- ISIN
- US98422T1007
- CUSIP
- 98422T100
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Oct 22, 2021
Highlights
- Market Cap
- $1.34B
- Enterprise Value
- $1.20B
- EPS (TTM)
- -$0.33
- Total Revenue (TTM)
- $53.48M
- Gross Profit (TTM)
- $39.30M
- EBITDA (TTM)
- -$42.74M
- Year Range
- $6.47 - $12.74
- Target Price
- $98.00
- ROA (TTM)
- -13.32%
- ROE (TTM)
- -30.01%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
XLO Performance Chart
Xilio Therapeutics, Inc. (XLO) is down 8.5% since the beginning of the year. At $8 per share, XLO is trading 35.6% below its 52-week high of $13.
Loading charts...
Returns By Period
Xilio Therapeutics, Inc. (XLO) has returned -8.51% so far this year and -13.34% over the past 12 months.
Xilio Therapeutics, Inc.
- 1D
- -0.61%
- 1M
- -1.56%
- YTD
- -8.51%
- 6M
- -17.04%
- 1Y
- -13.34%
- 3Y*
- -41.86%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.68%
- YTD
- 11.16%
- 6M
- 11.10%
- 1Y
- 27.46%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
XLO Monthly Returns History
Based on dividend-adjusted daily data since Oct 22, 2021, XLO's average daily return is -0.03%, while the average monthly return is -3.04%.
Historically, 40% of months were positive and 60% were negative. The best month was Oct 2024 with a return of +61.2%, while the worst month was Nov 2023 at -58.9%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 8 months.
On a daily basis, XLO closed higher 43% of trading days. The best single day was Feb 12, 2025 with a return of +125.3%, while the worst single day was Jun 2, 2025 at -34.6%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -7.08% | -11.20% | 13.71% | -5.83% | 6.82% | -3.07% | -8.51% | ||||||
| 2025 | -26.18% | 28.51% | -20.04% | 5.70% | 39.74% | -36.46% | -4.57% | 7.91% | 20.37% | -5.46% | -4.91% | -15.50% | -32.96% |
| 2024 | 18.18% | 9.08% | 52.33% | -3.70% | 3.85% | -12.27% | 0.24% | -9.68% | -8.18% | 61.23% | -14.17% | -12.39% | 73.64% |
| 2023 | 35.69% | -1.10% | -12.19% | 4.10% | -7.58% | -14.10% | 9.16% | 0.35% | -26.48% | 3.79% | -58.90% | -38.90% | -79.55% |
| 2022 | -14.94% | -13.45% | -39.98% | -50.07% | -15.01% | -2.67% | -0.68% | -22.76% | 29.91% | -19.59% | 3.42% | 11.16% | -83.19% |
| 2021 | 4.94% | -5.66% | 1.01% | 0.00% |
Benchmark Metrics
Xilio Therapeutics, Inc. has an annualized alpha of -18.19%, beta of 0.94, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since October 25, 2021.
- This stock participated in 119.11% of S&P 500 Index downside but only -95.66% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -18.19%
- Beta
- 0.94
- R²
- 0.02
- Upside Capture
- -95.66%
- Downside Capture
- 119.11%
Return for Risk
Risk / Return Rank
XLO ranks 26 for risk / return — below 26% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Xilio Therapeutics, Inc. (XLO) and compare them to S&P 500 Index.
| XLO | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.35 | 2.39 | -2.74 |
Sortino ratioReturn per unit of downside risk | -0.23 | 3.25 | -3.49 |
Omega ratioGain probability vs. loss probability | 0.97 | 1.43 | -0.46 |
Calmar ratioReturn relative to maximum drawdown | -0.40 | 3.11 | -3.51 |
Martin ratioReturn relative to average drawdown | -0.74 | 14.38 | -15.12 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Xilio Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Xilio Therapeutics, Inc. was 98.01%, occurring on Dec 20, 2023. The portfolio has not yet recovered.
The current Xilio Therapeutics, Inc. drawdown is 97.67%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2023 bear market2023 | -98.01%Dec 2023 | 2y 1mo | — | 4y 6moNov 2021 - now |
2021 correction2021 | -15.07%Nov 2021 | 0s | 1d | 1dNov 2021 - Nov 2021 |
2021 pullback2021 | -7.66%Nov 2021 | 0s | 3d | 3dNov 2021 - Nov 2021 |
2021 pullback2021 | -6.89%Nov 2021 | 3d | 4d | 7dNov 2021 - Nov 2021 |
2021 pullback2021 | -2.19%Oct 2021 | 0s | 2d | 2dOct 2021 - Oct 2021 |
Drawdown Indicators
| XLO | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.01% | -56.78% | -41.23% |
Max Drawdown (1Y)Largest decline over 1 year | -40.90% | -9.10% | -31.80% |
Max Drawdown (3Y)Largest decline over 3 years | -83.78% | -18.90% | -64.88% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -97.67% | 0.00% | -97.67% |
Average DrawdownAverage peak-to-trough decline | -88.71% | -10.72% | -77.99% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 22.27% | 1.97% | +20.30% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Xilio Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Xilio Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for XLO relative to other companies in the Biotechnology industry. Currently, XLO has a P/S ratio of 10.0. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for XLO in comparison with other companies in the Biotechnology industry. Currently, XLO has a P/B value of 18.5. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with XLO
Add Xilio Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with XLO